Funding source: This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea. (A070001)
Pharmacology and therapeutics
Is narrowband ultraviolet B monotherapy effective in the treatment of pityriasis lichenoides?
Version of Record online: 20 JUN 2013
© 2013 The International Society of Dermatology
International Journal of Dermatology
Volume 52, Issue 8, pages 1013–1018, August 2013
How to Cite
Park, J.-M., Jwa, S.-W., Song, M., Kim, H.-S., Chin, H.-W., Ko, H.-C., Kim, M.-B. and Kim, B.-S. (2013), Is narrowband ultraviolet B monotherapy effective in the treatment of pityriasis lichenoides?. International Journal of Dermatology, 52: 1013–1018. doi: 10.1111/j.1365-4632.2012.05814.x
Conflicts of interest: None.
- Issue online: 21 JUL 2013
- Version of Record online: 20 JUN 2013
- Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea. Grant Number: A070001
Pityriasis lichenoides (PL) is a self-limiting papulosquamous disease that may persist for years and is associated with a high relapse rate. To date, few comparative studies have investigated the efficacy of narrowband ultraviolet B (NB-UVB) phototherapy and other therapies in the treatment of PL.
The present study retrospectively compared the clinical efficacies of NB-UVB phototherapy, systemic therapy, and a combination of NB-UVB and systemic medication in the treatment of PL.
Seventy patients diagnosed with PL were enrolled in this study. They were divided into three subgroups: the NB-UVB treatment group; the systemic treatment group; and the combination treatment group. Therapeutic efficacy was evaluated according to whether the subjects demonstrated a complete response (> 90% improvement in skin lesions), partial response (50–90% improvement), or no response (< 50% improvement) to treatment.
A 91.9% complete response rate was achieved in the NB-UVB group, whereas only 69.2 and 80.0% of patients achieved a complete response in the systemic and combination treatment groups, respectively; these differences were not statistically significant. The mean treatment periods were 8.3, 5.3, and 7.9 weeks in the NB-UVB, systemic, and combination treatment groups, respectively; these differences were also not significant.
Monotherapy using NB-UVB is effective in achieving a complete response in the treatment of PL and thus eliminates the need for concurrent systemic medication.